Phantom limb sensations occur in virtually all patients at some time following amputation'. These phantom limb sensations usually appear within eight days after the amputation but may appear months or years later. We report the occurrence of severe phantom limb pain exacerbated by cytotoxic chemotherapy. The pain was resistant to high-dose opioids but readily controlled with intravenous ketamine. The pain returned on subsequent courses of chemotherapy, each time relieved by ketamine.
CASE REPORT
A 17-year-old, 74-kilogram boy had suffered intermittent bone pain in the right tibia for approximately eight months. Investigations, including biopsy, revealed osteosarcoma. Chemotherapy was initiated with adriamycin, ifosfamide, methotrexate and cisplatin. Fifteen weeks later he was admitted for right aboveknee amputation. Although he was pain free, he was offered a combined general and epidural anaesthetic technique to reduce the likelihood of phantom limb pain2. He refused placement of an epidural catheter and analgesia was initially managed postoperatively with morphine administered by a patient-controlled analgesia (PCA) device.
He was keen to be discharged home on the fourth postoperative day, despite developing some phantom limb sensations that consisted of tingling and itching. The phantom sensations increased in intensity and he was readmitted nine days later for pain control and the first postoperative course of chemotherapy.
On this admission, his femoral wound appeared to be healing satisfactorily but he complained of severe burning sensations on the lateral aspect of the phantom foot. He was commenced on carbamazepine and morphine with some improvement. Three days later his pain became unbearable, coinciding with his first postoperative course of chemotherapy.
Epidural analgesia was again considered but an evolving pancytopenia precluded this option. Despite large doses of morphine, both orally and parenterally, analgesia was inadequate with the parenteral dose of morphine (PCA) rapidly exceeding 400 mg per day. He became unco-operative and developed severe anorexia, drowsiness and constipation. Imipramine was added in escalating doses to 150 mg daily, limited by dry mouth and therapeutic serum levels; the carbamazepine was increased to 400 mg eight hourly. Right femoral and sciatic nerve blockade was performed using bupivacaine 0.5070 with no improvement in his phantom limb pain.
Finally a low-dose intravenous ketamine infusion was commenced at 10 mg per hour (0.14 mg/kg/hr). Within four hours his pain began improving and within 48 hours he had completely ceased oral and peA morphine. His phantom limb began' 'shrinking" and remaining sensations were described as non-painful. He did not appear somnolent during the day, began sleeping throughout the night, and showed no evidence of any hallucinations.
After four days of a continuous infusion of ketamine he was changed to a PCA device to allow greater dosing flexibility. Ketamine boluses of 3 mg with a lockout of 15 minutes were given with a background infusion of 6 mg/hr. On this regimen the dose of ketamine averaged 9 mg/hr (0.12 mg/kg/hr). With experience, he preferred a continuous infusion and he was discharged home on ketamine 9 mg/hr, which was subsequently weaned over the next five days. In all, he received a total of 14 days treatment with ketamine.
He was subsequently re-admitted for two further courses of chemotherapy, both of which seemed to exacerbate his phantom limb pain. On each occasion he was offered intravenous morphine or ketamine and he chose ketamine each time with satisfactory results.
DISCUSSION
The aetiology and pathophysiological mechanisms underlying phantom limb and related phenomena are still unknown, but probably involve peripheral and central (both spinal and supraspinal) mechanisms. Phantom phenomena occur in the majority of patients with any kind of deafferentation such as amputation, peripheral nerve injury or spinal injury'. Most amputees report phantom limb sensations almost immediately after amputation of a limb; however, the phantom sensation usually fades during the first year. As many as 70070 of amputees suffer phantom limb pain3. The pain is typically described as occuring in the extremity, either continuously or intermittent, and of varying intensity. The quality varies greatly but is predominantly a burning, aching, throbbing, or shooting pain.
Reappearance of quiescent phantom limb has been reported during spinal anaesthesia', epidural anaesthesia S , during labour 6 and in other stressful conditions. Emotional disturbance is reported to be one of the major factors which trigger pain in amputees l • To our knowledge, there are no reports in the literature of phantom limb pain appearing during cytotoxic chemotherapy.
Cytotoxic agents such as the vinca alkaloids and cisplatin may be associated with neurotoxicity. The mechanism of neurotoxicity and cancer cell cytotoxicity involves interaction with tubulin, an intracellular protein which forms microtubules. Microtubules are involved in diverse cellular processes including axoplasmic transport, neurite outgrowth and mitotic spindle formation 7 • Clinical manifestations of neurotoxicity are consistent with a dose-dependent ganglionopathy of both sensory and autonomic nerves 8 • Cisplatin appears to inhibit RNA and neuropeptide synthesis following binding to DNA and disruption of nucleoW; the mechanism of resultant nerve injury is uncertain, however neuropeptide Y and vaso-active intestinal peptide have been implicated"'.
Thus chemotherapy with agents such as cisplatin could further exacerbate the spinal dorsal horn "sprouting" and neuro-anatomical re-organization that follows nerve injury and be associated with neuropathic pain phenomena through maladaptive plasticity'o.
Injury may induce a hyperexcitable state in the dorsal horn neurones called "wind-up", a process involving the N-methyl-D-aspartate (NMDA) receptor. This receptor may be involved in sustaining nociceptive transmission in the spinal cord, particularly when the nociceptive input in the peripheral nerves is declining I I. Klepstad 12 states that ketamine binds specifically to a site associated with the NMDA receptor-monitored ion channel and inhibits the action of excitatory amino acid neurotransmitters in a non-competitive manner. He proposes that ketamine analgesia is due to inhibition of this NMDA receptor-operated ion channel, especially analgesia following peripheral nerve injury.
There is no consistently effective treatment for persistent phantom limb pain. Half of those with persistent, long-term phantom pain fail to respond to any approach 3 .
Ketamine has been reported to be of use in cancer pain'3 and phantom limb pain l4 • It has been used intravenously, intramuscularly, subcutaneously, epidurally and on demand IS. Plasma concentrations of ketamine greater than 100-150 ng/ml are associated with analgesia without impairment of consciousness, while concentrations greater than 650 ng/ml resulting from a dose of 0.5 to 2 mg/kg are associated with anaesthesia 's . The dose of ketamine used in this case of 0.12 mg/kg/hr would thus be expected to produce a plasma concentration well below that required for anaesthesia and is almost identical to the dose used by Stannard et al '4 • The above mechanisms may explain the apparent beneficial effect of ketamine in phantom limb pain and the uniformly poor results observed when using opioids". We confirm that low-dose intravenous ketamine may be an option for treatment of acute phantom limb pain.
